GeneOS

7 articles about GeneOS

• Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response

  8/22/2023

  Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC).

• Geneos Therapeutics Nominated for 2023 Prix Galien USA Startup Award

  7/28/2023

  Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines, announced that it has been nominated for the Prix Galien Startup Award for 2023.

• Geneos Therapeutics Secures $5 Million in Series A3 Financing

  4/12/2023

  Geneos Therapeutics today announced that it has secured $5 million in its Series A3 round.

• Geneos Announces Expansion of Leadership Team

  10/12/2022

  Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that the company has expanded its leadership team and has elected Dr. Laurent Humeau to the company's board of directors.

• Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program

  6/3/2021

  Highlighting its Phase Ib/IIa trial in advanced hepatocellular cancer and a case study for treatment of anaplastic astrocytoma at the American Society of Clinical Oncology (ASCO) Data from first 10 patients in the HCC trial demonstrates clinical responses

• Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

  3/3/2021

  Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma

• Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies

  2/21/2019

  Geneos has Licensed Immunotherapy Platform from Inovio Pharmaceuticals for Developing Personalized Cancer Treatments